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INTRODUCTION
Infection with human hepatitis B virus (HBV) can lead
to high morbidity and mortality due to the development of
end-stage liver diseases. It is estimated that more than 350
million people worldwide are infected with HBV (1). Among
infected individuals, about 5-10% of adults and more than
90% of children become persistently infected by the virus
and develop liver diseases. The clinical outcome of the infec-
tion is variable and may result in spontaneous recovery, inac-
tive HBV surface antigen (HBsAg) carrier state, chronic
hepatitis, liver cirrhosis, or hepatocellular carcinoma (2, 3).
The precise mechanisms leading to these various outcomes
are not clearly defined yet but it has been perceived that host
immune responsiveness is the critical factor.
It has been demonstrated that vigorous CD4+ and CD8+
T lymphocyte responses to various HBV antigens were asso-
ciated with HBV self-elimination, while insufficient CD4+
T cell help and defective CD8+ T cell repertoire at the early
stages of infection were connected to viral persistence (4, 5).
Due to the specific antigen presenting function of human
leukocyte antigens (HLA) in immune responsiveness, the
contribution of HLA to the outcome of HBV infection has
been studied extensively in different populations. However,
data have shown some inconsistencies with regard to HLA
effects on HBV clearance or persistence in different ethnic
and racial groups. Extensive HLA polymorphism contributes to
the selection of antigenic peptides for presentation to T lym-
phocytes resulting in different immune responses to infec-
tion amongst individuals. Furthermore, HLA molecules
differing only at 1-2 amino acids showed different peptide
binding preference (6). This implies that HLA analysis for
disease association studies requires high resolution typing to
better understand the mechanisms involved. 
Korea is an endemic area for HBV infection and about 5%
of the population has been shown to be chronically infected
(7). Two studies regarding HLA association in Koreans have
been reported and consistently demonstrated that DR13 was
associated with self-elimination of HBV (8, 9). However,
these studies to clarify the HLA association in the popula-
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Human Leukocyte Antigen Class II Association with Spontaneous
Recovery from Hepatitis B Virus Infection in Koreans: Analysis at the
Haplotype Level
It has been speculated that human leukocyte antigen (HLA) alleles are associated
with the outcome of hepatitis B virus (HBV) infection although the data obtained
from various populations have shown some inconsistencies. A total of 464 HBV-
infected Korean individuals (80 spontaneously recovered [SR] and 384 chronically
infected [CI]) were selected to investigate the association of HLA class II alleles
with the viral clearance and persistence. Our results showed that: 1) multiple HLA
class II alleles and haplotypes were associated with viral clearance (DRB1*1302,
DRB1*1502, DQB1*0302, DQB1*0609, and related-haplotypes) and persistence
(DRB1*0701, DQB1*0301, and related-haplotypes); 2) DRB1*1302 and DQB1*
0609 were more strongly associated with viral clearance. And the association of
DQB1*0609 (pc=0.0084; OR, 7.24) with vial clearance was much stronger than
previously recognized, DRB1*1302 (pc=0.0038; OR, 4.34); and 3) linkage to a
specific DPB1 allele in a haplotype strengthened the association with viral clear-
ance, although DPB1 itself was not associated with the outcome. These results
indicate the existence of multiple factors controlling viral clearance in the HLA class
II gene region. Further extended investigation on the genetic factors related to the
outcome of HBV infection will provide valuable insights into the understanding of
the mechanisms involved.
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tion were limited in several respects. They examined only
HLA-A, -B, and -DR at low resolution and used patients
with organ transplants as their study subjects. Therefore, the
purpose of this study was to further investigate the HLA
association with the outcome of HBV infection using high
resolution typing of HLA class II loci (HLA-DRB1, -DQB1,
and -DPB1). The impact of HLA diversity was evaluated
on viral clearance and persistence. 
MATERIALS AND METHODS 
Study subjects
A total of 464 Koreans who had been exposed to HBV as
detected by the presence of antibody to HBV core antigen
(anti-HBc) IgG, were enrolled from the outpatient clinics of
the Gastroenterology Department of Ajou University Hospi-
tal (Suwon, Korea) between March and December 2002. Study
subjects were divided into two groups based on the status of
HBV serologic markers exhibited for more than 6 months.
The spontaneously recovered (SR) group included 80 indi-
viduals (60 males and 20 females, aged 19-70 yr, mean±
SD, 47.9±10.3) who were HBsAg negative, anti-HBc pos-
itive and antibody to HBV surface antigen (anti-HBs) posi-
tive, and had no evidence of liver function abnormalities and
of previous chronic liver disease based on their medical his-
tory. The chronically infected (CI) group included 384 indi-
viduals (283 males and 101 females, aged 16-77 yr, mean±
SD, 41.0±10.3) who were HBsAg and anti-HBc positive,
and anti-HBs negative. They were regularly followed with
blood tests for serum alanine aminotransferase (ALT)/aspar-
tate aminotransferase (AST), hepatitis B e antigen (HBeAg)/
antibody to hepatitis B e antigen (anti-HBe) and alpha feto-
protein (AFP), and with radiographic tests of the liver (com-
puted tomography or ultrasonography) at an interval of every
6 months for more than a year. HBV-DNA was detected by
Digene Hybrid Capture II Assay (Digene Diagnostics, Bel-
tsville, MD, U.S.A.); the detection limit of the test was 0.5
pg/mL. None of the patients had hepatocellular carcinoma.
Patients who were positive for anti-HBs and negative for
anti-HBc IgG, and patients with other types of chronic liver
disease such as alcoholic liver disease, chronic hepatitis C,
steatohepatitis, and Wilson’s disease, were excluded from
this study. Informed consents were obtained from each sub-
ject, and the Institutional Review Board of Human Research
of Ajou University Hospital approved the study protocol.
HLA allelic typing
Genomic DNA was extracted from peripheral blood mono-
nuclear cells of the study subjects using the method of Miller
and colleagues (10). Allele-level genotypes of the HLA-
DRB1, -DQB1, and -DPB1 genes from each study sample
were obtained by direct DNA sequence analysis based on
the procedures described previously (11-13). Briefly, the
polymorphic exon 2 of the gene was amplified using group-
specific (HLA-DRB1) or locus-specific (HLA-DQB1, and -
DPB1) primer sets. Automated cycle sequencing using dye
terminator chemistry (v3.1, Applied Biosystems, Foster City,
CA, U.S.A.) was performed on the amplified gene product
and the amplicon was analyzed on an ABI3100 Genetic Ana-
lyzer (Applied Biosystems). Data analysis was performed with
Sequence Navigator and MatchTool software (PE-Applied
Biosystems Inc., U.S.A.). Homozygosity was assumed when
no other HLA-DRB1, -DQB1, and -DPB1 allele was detect-
ed upon direct DNA sequence analysis.
Statistical analysis
Statistical analyses were done using SAS (version 8.01, SAS
institute, Cary, NC). Haplotype reconstruction was imple-
mented by PHASE (14). Hardy-Weinberg equilibrium for
all loci and linkage disequilibrium for all pairs of loci were
tested using Arlequin (version 2.0, Genetics and Biometry
Laboratory, University of Geneva, Switzerland). Phenotype
frequencies of HLA-DRB1, -DQB1, and -DPB1 alleles as
well as haplotype frequencies of DRB1-DQB1, DQB1-DPB1,
and DRB1-DQB1-DPB1 in two study groups were com-
pared. Alleles (<3%) and haplotypes (<2%) with low frequen-
cies were not analyzed due to inadequate statistical power.
Some general characteristics were compared between the two
study groups using t-test and chi-square test. Odd ratios (ORs)
with 95% confidence intervals (95% CI) and p values for
alleles and haplotypes associated with the outcome of HBV
infection were calculated by logistic regression analysis adjust-
ing for age and sex. When one element in the 2×2 table
was zero, the p value was calculated by a chi-square test in
haplotype analysis. Statistical significance was assumed at
p<0.05. When the p value was less than 0.05, a Bonferroni
correction was applied by multiplying the p value by the
number of comparisons made. 
RESULTS 
Characteristics of study groups
Among HBV-exposed subjects including SR group (n=
80) and CI group (n=384), the SR group (47.9±10.3 yr
old) was somewhat older than the CI group (41.0±10.3 yr
old) (p<0.0001). However, regarding gender, there was no
significant difference between the SR group (% male=75.0)
and the CI group (% male=73.7) (p>0.1).
Alleles associated with HBV clearance or persistence
Using direct DNA sequencing analysis, class II allele geno-840 S.W. Cho, J.Y. Cheong, Y.S. Ju, et al.
types at the four-digit level were obtained from the study
subjects. A total of 31 HLA-DRB1, 16 HLA-DQB1, and
23 HLA-DPB1 alleles were identified. Distribution of the
alleles for all loci were consistent with Hardy-Weinberg equi-
librium in the SR and CI groups, respectively (p>0.05). 
Phenotype frequencies of HLA class II alleles in the two
study groups are listed in Table 1. The frequencies of DRB1*
1302 (17.50% vs. 4.95%, p=0.0002, OR, 4.34) and DQB1*
Allele
SR 
n=80 (PF, %)
CI
n=384 (PF, %)
p value pc value OR (95% CI)
DRB1*
0101 7 (8.75) 38 (9.90) 0.9797 --
0301 2 (2.50) 20 (5.21) 0.4144 --
0403 5 (6.25) 14 (3.65) 0.5676 --
0405 10 (12.50) 57 (14.84) 0.5411 --
0406 10 (12.50) 27 (7.03) 0.1351 --
0410 3 (3.75) 8 (2.08) 0.1776 --
0701 7 (8.75) 69 (17.97) 0.0458 NS 0.43 (0.19-0.98)
0802 6 (7.50) 16 (4.17) 0.2157 --
0803 10 (12.50) 75 (19.53) 0.2037 --
0901 18 (22.50) 83 (21.61) 0.9582 --
1101 8 (10.00) 47 (12.24) 0.7600 --
1201 6 (7.50) 35 (9.11) 0.7519 --
1202 5 (6.25) 39 (10.16) 0.1581 --
1301 3 (3.75) 7 (1.82) 0.2292 --
1302 14 (17.50) 19 (4.95) 0.0002 0.0038 4.34 (2.00-9.40)
1401 5 (6.25) 27 (7.03) 0.9343 --
1405 6 (7.50) 26 (6.77) 0.9780 --
1501 12 (15.00) 59 (15.36) 0.6098 --
1502 12 (15.00) 32 (8.33) 0.0376 NS 2.21 (1.05-4.67)
DQB1*
0201 2 (2.50) 20 (5.21) 0.4144 --
0202 7 (8.75) 65 (16.93) 0.0761 --
0301 17 (21.25) 126 (32.81) 0.0470 NS 0.55 (0.30-0.99)
0302 20 (25.00) 49 (12.76) 0.0172 NS 2.12 (1.14-3.93)
0303 21 (26.25) 96 (25.00) 0.9281 --
0401 11 (13.75) 56 (14.58) 0.7121 --
0402 6 (7.50) 22 (5.73) 0.3534 --
0501 9 (11.25) 50 (13.02) 0.8812 --
0502 1 (1.25) 27 (7.03) 0.0852 --
0503 8 (10.00) 41 (10.68) 0.8454 --
0601 20 (25.00) 99 (25.78) 0.8720 --
0602 12 (15.00) 54 (14.06) 0.8134 --
0604 6 (7.50) 14 (3.65) 0.1274 --
0609 8 (10.00) 6 (1.56) 0.0006 0.0084 7.24 (2.35-22.27)
DPB1*
0201 32 (40.00) 144 (37.50) 0.8808 --
0202 7 (8.75) 26 (6.77) 0.8295 --
0301 6 (7.50) 27 (7.03) 0.8432 --
0401 9 (11.25) 36 (9.38) 0.5104 --
0402 11 (13.75) 40 (10.42) 0.4062 --
0501 51 (63.75) 264 (68.75) 0.4223 --
0901 10 (12.50) 26 (6.77) 0.0690 --
1301 5 (6.25) 50 (13.02) 0.0710 --
1401 2 (2.50) 17 (4.43) 0.4373 --
1701 4 (5.00) 17 (4.43) 0.9014 --
Table 1. Comparison of HLA class II phenotype frequencies between HBV spontaneously recovered (SR) and chronically infected
(CI) groups
PF, phenotype frequency of HLA allele is presented in percentage; pc value, p value corrected by multiplying the number of alleles tested (19 for
DRB1, 14 for DQB1); OR, odds ratio (SR group vs. CI group); CI, confidence interval; NS, statistically not significant after correction.
Alleles with a phenotype frequency >3% are listed.
Only significant pc values (<0.05) are presented.Association of HLA Class II and HBV in Korea 841
0609 (10.00% vs. 1.56%, p=0.0006, OR, 7.24) were sig-
nificantly higher in the SR group compared to the CI group.
Their statistical significance was maintained after correction
of the p values (pc=0.0038 and pc=0.0084, respectively). The
frequencies of DRB1*1502 and DQB1*0302 were higher
in the SR group, while the frequencies of DRB1*0701 and
DQB1*0301 were higher in the CI group. However, pvalues
were not statistically significant after the correction (Table 1).
Comparison of the impact of DRB1*1302 and DQB1*0609
on HBV clearance
As described above, two alleles (DRB1*1302 and DQB1*
0609) were significantly associated with HBV clearance.
Interestingly, all of the individuals carrying DQB1*0609
were DRB1*1302-positive in this study. This is due to the
strong linkage disequilibrium between these two alleles in
Koreans as previously described (15). Thus, the statistics for
these two alleles might be distorted and an additional analy-
sis was necessary to estimate the impact of the two alleles on
HBV clearance. Fortunately, DRB1*1302 also showed strong
linkage disequilibrium with DQB1*0604 in the study popu-
lation (15). About 42% of DRB1*1302+ Korean individu-
als carry DQB1*0609 and the remainder (58%) carry DQB1*
0604. Thus, the significance of those two clearance alleles
were indirectly evaluated by comparing haplotype frequen-
cies of DRB1*1302-DQB1*0609 and DRB1*1302-DQB1*
0604 in the two study groups. As shown in Table 2, the fre-
quency of DRB1*1302-DQB1*0609 was much higher in
the SR group than in the CI group with a statistical signifi-
cance (5.63% vs. 0.78%, p=0.0002, OR, 7.57), and its sig-
nificance remained after correcting the p value (pc=0.0040).
Although it was still elevated in the SR group (3.75% vs.
1.82%), the frequency of the second haplotype, DRB1*1302-
DQB1*0604, was not statistically different between the two
groups. In conclusion, DQB1*0609 was the primary allele
associated with HBV clearance. The observed association of
clearance with DRB1*1302 might be due to the DRB1 allele
itself and/or to the linked DQB1*0609.
Haplotypes associated with HBV clearance or persistence
Two- and three-locus HLA class II haplotypes associated
with viral clearance and persistence are listed in Table 3. All
of the haplotypes, except two (DQB1*0303-DPB1*0201,
DRB1*0901-DQB1*0303-DPB1*0201), carried at least
DRB1*-DQB1* SR 
n=160 (HF, %)
CI
n=768 (HF, %)
p value pc value OR (95% CI)
1302-0604 3.75 1.82 0.1267 --
1302-0609 5.63 0.78 0.0002 0.0040 7.57 (2.66-21.58)
Table 2. Comparison of DRB1*1302-related haplotype frequencies between the SR and CI groups
SR, spontaneously recovered; CI, chronically infected; HF, haplotype frequency is presented in percentage; pc value, p value corrected by multiply-
ing the number of haplotypes tested (20 for DRB1-DQB1); OR, odds ratio (SR group vs. CI group); CI, confidence interval.
Only significant pc values (<0.05) are presented.
SR 
n=160 (HF, %)
Haplotype
CI
n=768 (HF, %)
p value pc value OR (95% CI)
Viral clearance
DRB1*1302-DQB1*0609 5.63 0.78 0.0002 0.0040 7.57 (2.66-21.58)
DQB1*0609-DPB1*0201 3.75 0.39 0.0013 0.0260 9.93 (2.46-40.15)
DRB1*1302-DQB1*0609-DPB1*0201 3.75 0.26 0.0010 0.0190 14.92 (2.98-74.63)
DRB1*1502-DQB1*0601 8.12 3.91 0.0239 NS 2.18 (1.11-4.27)
DQB1*0601-DPB1*0901 6.83 2.78 0.0144 NS 2.55 (1.21-5.40)
DRB1*1502-DQB1*0601-DPB1*0901 6.88 2.84 0.0149 NS 2.53 (1.20-5.33)
DQB1*0302-DPB1*0501 7.26 2.56 0.0043 NS 2.97 (1.41-6.26)
DQB1*0303-DPB1*0201 7.44 2.98 0.0091 NS 2.61 (1.27-5.38)
DRB1*0901-DQB1*0303-DPB1*0201 6.60 2.53 0.0103 NS 2.74 (1.27-5.91)
Viral persistence*
DQB1*0301-DPB1*0201 0 4.01 0.0100 NS NA
DQB1*0202-DPB1*1301 0 3.81 0.0121 NS NA
DRB1*0701-DQB1*0202-DPB1*1301 0 3.82 0.0121 NS NA
Table 3. Two- and three-locus haplotypes associated with viral clearance and persistence
SR, spontaneously recovered; CI, chronically infected; HF, frequency of allele or haplotype is presented in percentage; pc value, p value corrected
by multiplying the number of haplotypes tested (20 for DRB1-DQB1; 20 for DQB1-DPB1; 19 for DRB1-DQB1-DPB1); OR, odds ratio (SR group vs. CI
group); CI, confidence interval; NS, statistically not significant after correction (pc->0.05); NA, not applicable.
*, p value was calculated by chi-square test.842 S.W. Cho, J.Y. Cheong, Y.S. Ju, et al.
one of the outcome-related alleles (Table 1). For example,
three DRB1*1302- and DQB1*0609-related haplotypes
(DRB1*1302-DQB1*0609 (pc=0.0040), DQB1*0609-
DPB1*0201 (pc=0.0260), DRB1*1302-DQB1*0609-
DPB1*0201 (pc=0.0190)) were strongly associated with
viral clearance as DRB1*1302 and DQB1*0609 themselves
were. The haplotypes maintained statistical significances
after correction of the p values. Other haplotypes associated
with viral clearance were DRB1*1502- and DQB1*0302-
related haplotypes. Haplotypes associated with viral persis-
tence were DQB1*0301- and DRB1*0701-related haplo-
types. However, p values for those haplotypes were not sta-
tistically significant after the correction (Table 3).
Although none of the DPB1 allele appeared to be associated
with the outcome of HBV infection (Table 1), there was an
indirect association of DPB1 with viral clearance observed
at the haplotype level (Table 3). On a haplotype (DQB1*
0303-DPB1*0201, p=0.0091, OR, 2.61) associated with
viral clearance with a statistical significance, neither DQB1*
0303 (26.25% vs. 25.00%) nor DPB1*0201 (40.00% vs.
37.50%) alone was associated with viral clearance as shown in
Table 1. However, a haplotype consisting of these two alleles
appeared to be associated with viral clearance. Furthermore,
the OR value of its 3-locus haplotype, DRB1*0901-DQB1*
0303-DPB1*0201 (OR, 2.74), was similar to that of DQB1*
0303-DPB1*0201 (OR, 2.61). We could observe a similar
phenomenon in another example. DQB1*0609 (OR, 7.24)
was strongly associated with viral clearance as described
above. However, linking this allele to statistically insignifi-
cant DPB1*0201 again in a haplotype DQB1*0609-DPB1*
0201 increased the OR value (OR, 9.93). In a three-locus
haplotype, DRB1*1302-DQB1*0609-DPB1*0201, the
OR value was even higher (OR, 14.92).
DISCUSSION
From the study of the HLA association with the outcome
of HBV infection, we found that two HLA class II alleles
are strongly associated with viral clearance. The first allele
was DRB1*1302 and this result was concordant with two
previous Korean studies that demonstrated that DR13 was
associated with self-elimination of HBV (8, 9). In addition,
DRB1*1302 has been consistently reported as a factor asso-
ciated with protection against persistent HBV infection in
two other racial groups, Africans (16) and Caucasians (17,
18). Identification of the same HLA allele and/or serologic
type from various populations strongly suggests that there
is at least one common element restricting HBV in humans.
A beneficial effect of DR13 on HBV infection has also been
confirmed by functional assay. Diepolder et al. demonstrat-
ed that DR13-positive individuals showed a more vigorous
CD4+ T cell response to HBV core antigen (HBcAg) than
DR13-negative patients (19). DR13-restricted CD4+ T cell
epitopes of HBcAg were later discovered (20).
The second allele associated with viral clearance was DQB1*
0609, which is in strong linkage disequilibrium with DRB1*
1302 in the study population. The impact of the DQB1*
0609 allele on HBV clearance was indirectly analyzed by com-
paring frequencies of the two DRB1*1302-positive haplo-
types, DRB1*1302-DQB1*0609 and DRB1*1302-DQB1*
0604, between the two study groups. The result indicates
that DQB1*0609 has a much stronger association with HBV
clearance than DRB1*1302 and we believe that DQB1*
0609 is the primary class II allele associated with viral clear-
ance. This hypothesis is supported by several previous stud-
ies. First, there has been a report that the phenotype frequen-
cy of DQw1 was significantly lower in Dutch patients with
chronic active HBV infection (21) (DQB1*0609 is one of
the alleles encoding the DQw1 molecule). In addition, a
study in Gambians indicated that the frequency of DQB1*
06 linked to DRB1*1302 was significantly higher in chil-
dren (11.9% vs. 6.5%, p=0.06) and adults (9.2% vs. 0%, p=
0.05) who cleared the virus than in individuals who carried
the virus persistently (16). Later, DQB1*0609 was found to
be relatively frequent in Gambians (DQB1*0609=4.4%;
DQB1*0604=0.7%) (22). Lastly, it has been demonstrated
that DR13-positive individuals exhibited a more vigorous
CD4+ T cell response to HBcAg than DR13-negative indi-
viduals during acute HBV infection (19). However, less than
10% of the HBc-specific CD4+ T cell clones derived from
DR13-positive patients were DR13-restricted. This result
left open the possibility that the majority of the CD4+ T
cell clones (>90%) might be restricted to other HLA class
II molecules including DQw1 encoded by a DQB1*06 allele
in DR13-positive individuals. 
Therefore, for the first time, we have shown that DQB1*
0609 is the primary allele associated with HBV clearance
and its association is much stronger than previously found
for DRB1*1302. In most of the previous association studies
on HBV clearance, DQB1 high resolution typing was not
performed. Only three studies so far analyzed DQB1 at allele
resolution; however, the frequencies of DQB1*0609 might
have been too low in the study populations to catch its sta-
tistical significance (18, 23, 24). That could be the reason
why DQB1*0609 has not been identified thus far with HBV
clearance. Our hypothesis needs to be confirmed by further
studies in populations expressing a high frequency of this
allele. 
Several additional alleles were found to be associated with
the outcome of HBV infection in this study, although the
result did not reach statistical significance. The increased
frequency of DRB1*1502 in the SR group was consistent
with previous studies in Qartar (25) and China (26). Like-
wise, the higher frequencies of DRB1*0701 (9, 25) and
DQB1*0301 (23, 24) in the CI group were consistent with
previous reports. One of the previous studies analyzed a Kore-
an population and found significant association of DR7 withAssociation of HLA Class II and HBV in Korea 843
HBV persistence (pc<0.001) (9). Another study in the same
population found a high frequency of DR9 (p<0.001), instead
of DR7, in the CI group (8). These discrepancies might stem
from differences in the study subjects. In our study, the study
samples were recruited from outpatient clinics based on the
HBV serologic markers. Previous studies analyzed the com-
piled HLA typing data of individuals undergoing organ
transplantation and their donors where HLA matching bet-
ween patient and donor is beneficial. Thus, the HLA frequen-
cies in those studies could have been biased. DQB1*0302,
found in this study associated with HBV clearance, has not
been identified previously.
During the analysis of HLA class II multi-locus haplo-
types, we found several related haplotypes carrying outcome-
related alleles. Interestingly, association with viral clearance
is significantly intensified on DQB1-DPB1 haplotypes con-
sisting of a DQB1 allele (either a statistically insignificant
allele [e.g., DQB1*0303] or a clearance-associated allele [e.g.,
DQB1*0609]) and the statistically insignificant DPB1*
0201, compared to OR values of the DQB1 allele alone. These
results indicate that a DPB1 allele in combination with a
DQB1 allele has either a cooperative (or synergistic) protec-
tive effect since DPB1*0201 (40.0% vs. 37.5%) alone has
no effect. Alternatively, there might be another gene influ-
encing the outcome of HBV infection located near the DPB1
gene. Several polymorphic genes, such as LMP, DM, and DO,
whose gene products assist in antigen binding to the HLA
molecules in a cell, are known to be located between DQB1
and DPB1 genes (27). Further extended investigation of these
polymorphic genes might elucidate the cooperative (or syn-
ergistic) modification of immune responsiveness to HBV
infection. Whether it is a cooperative (or synergistic) interac-
tion or a closely linked gene, factor other than DR and DQ
alleles might be involved in viral clearance.
The DRB1*1302-DQB1*0609-DPB1*0201 haplotype
shows the strongest protective effect against HBV (pc=0.0190,
OR, 14.92). Based on the results obtained from this study,
it is most likely that the strong protective effect of the hap-
lotype against HBV persistence might derive from three differ-
ent factors: DRB1*1302, DQB1*0609, and another unknown
factor linked to DPB1 as just described. Further investiga-
tions should be made to identify this.
In summary, multiple HLA class II alleles and related hap-
lotypes are associated with viral clearance and persistence in
Koreans. In specific, DRB1*1302 and DQB1*0609 are
strongly associated with viral clearance. However, unexpect-
edly, the association of DQB1*0609 is much stronger than
that of DRB1*1302. In addition, the association with a sta-
tistically insignificant DPB1 allele in a haplotype strength-
ens the association with viral clearance, hinting that another
unknown factor might be involved in viral clearance. These
results may reflect the existence of multiple factors control-
ling viral clearance encoded in the HLA class II gene region.
Further extended investigation on the genetic factors relat-
ed to the outcome of HBV infection will provide valuable
insights into the understanding of the mechanisms involved. 
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